| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/10/2002 | WO2001049281A3 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| 05/10/2002 | WO2001046198A3 Nonpeptide kappa opioid receptor antagonists |
| 05/10/2002 | WO2001043733A3 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| 05/10/2002 | WO2001041768A3 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 05/10/2002 | WO2001038326A3 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/10/2002 | WO2001038324A3 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/10/2002 | WO2001036618A3 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced |
| 05/10/2002 | WO2001036487A3 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/10/2002 | WO2001032709A3 Polypeptides with non-natural primary signalling motifs |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001030972A3 Regulation of gene expression by neuroleptic agents |
| 05/10/2002 | WO2001030332A3 Methods of protecting neuronal function |
| 05/10/2002 | WO2001029036A3 Allosteric sites on muscarinic receptors |
| 05/10/2002 | WO2001028545A3 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 05/10/2002 | WO2001027135A3 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/10/2002 | WO2001024784A3 New use |
| 05/10/2002 | WO2001023389A3 Certain alkylene diamine-substituted heterocycles |
| 05/10/2002 | WO2001023386A3 Benzodiazepin derivatives, the production and use thereof |
| 05/10/2002 | WO2001016359A3 Screen for axon viability |
| 05/10/2002 | WO2001000186A3 New use of 1,2,4-triazolo'1,5-a! pyrimidines |
| 05/10/2002 | WO2000071106A3 Method of treating weight gain |
| 05/10/2002 | WO2000067761A8 Compositions and methods for identifying antigens which elicit an immune response |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000054802A3 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | CA2431641A1 Treatment of motor fluctuations |
| 05/10/2002 | CA2428023A1 Methods and compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 05/10/2002 | CA2427952A1 Dna expression vectors |
| 05/10/2002 | CA2427850A1 Interferons, uses and compositions related thereto |
| 05/10/2002 | CA2427629A1 Gene regulation therapy involving ferritin |
| 05/10/2002 | CA2427557A1 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | CA2427533A1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427394A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | CA2427194A1 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | CA2427193A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | CA2426977A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | CA2426894A1 Method of treating and preventing migraine headaches |
| 05/10/2002 | CA2426658A1 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | CA2425286A1 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 05/10/2002 | CA2425285A1 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| 05/10/2002 | CA2424598A1 Radiopharmaceuticals for diagnosing alzheimer's disease |
| 05/10/2002 | CA2421705A1 New treatments for restless legs syndrome |
| 05/10/2002 | CA2395324A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | WO2002036153A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | US20020055632 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction |
| 05/09/2002 | US20020055630 Process for preparation of cyclopenta [b] [1,4] diazepino [6,7,1-hi] indole derivatives |
| 05/09/2002 | US20020055616 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 05/09/2002 | US20020055615 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 05/09/2002 | US20020055534 Method for treating neurodegeneration |
| 05/09/2002 | US20020055527 Thiazolium compounds and treatments of disorders associated with protein aging |
| 05/09/2002 | US20020055526 Modulators of SKCa, IKCa and BKCa channels. |
| 05/09/2002 | US20020055524 Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor |
| 05/09/2002 | US20020055521 Analogs of cocaine |
| 05/09/2002 | US20020055519 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| 05/09/2002 | US20020055518 Polyoxyethylated hydroxyesters of rapamycin useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease. |
| 05/09/2002 | US20020055508 Benzofurazan compounds which enhance AMPA receptor activity |
| 05/09/2002 | US20020055507 Ureas and thioureas inhibit production of cytokines |
| 05/09/2002 | US20020055504 Acylating a cyclopentaindolemethylamine and cyclizing and reducing the product |
| 05/09/2002 | US20020055503 Treatment of seizures resulting from, e.g. epileptic attack. |
| 05/09/2002 | US20020055501 Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. |
| 05/09/2002 | US20020055500 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds |
| 05/09/2002 | US20020055484 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 05/09/2002 | US20020055476 RAMPs are small proteins that transport calcitonin-receptor-like proteins to the plasma membrane; drug screening |
| 05/09/2002 | US20020055467 Truncated neublastin, of the glial cell-derived nerve growth factor (GDNF) subfamily; when dimerized, binds to a RET (a receptor tyrosine kinase) polypeptide |
| 05/09/2002 | US20020055163 Amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides; useful in the development of human therapeutics and diagnostic formulations |
| 05/09/2002 | US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies |
| 05/09/2002 | US20020054926 Administering tobacco extract, Yerbamate extract, and extract of chewing gum and lozenges for increasing levels of norepinephrine, dopamine, and serotonin to treat psychological disorders and aid in smoking cessation |
| 05/09/2002 | US20020054920 Antistress composition for a stress prevention and treatment |
| 05/09/2002 | US20020054907 Multiparticulate modified release composition |
| 05/09/2002 | US20020054904 Stable pergolide mesylate and process for making same |
| 05/09/2002 | US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent |
| 05/09/2002 | US20020054876 Treatment of Alzheimer's disease |
| 05/09/2002 | US20020054856 Nicotine mucosal spray |
| 05/08/2002 | EP1203816A1 Amyloid beta protein agglutination controlling factor |
| 05/08/2002 | EP1203766A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 05/08/2002 | EP1203764A1 Benzamidine derivatives with LTB4-antagonistic activity |
| 05/08/2002 | EP1203584A1 Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
| 05/08/2002 | EP1203581A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 05/08/2002 | EP1203239A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 05/08/2002 | EP1203233A1 Method for identifying modulating compounds of neurotransmitters |
| 05/08/2002 | EP1203081A2 Human intracellular signaling molecules |
| 05/08/2002 | EP1203025A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND $g(b)1 INTEGRINS |
| 05/08/2002 | EP1203024A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 05/08/2002 | EP1203023A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 05/08/2002 | EP1203020A1 Modulation of human sodium channels in dorsal root ganglia |
| 05/08/2002 | EP1203019A1 Peptides containing n-substituted l-amino acids for preventing beta-strand association |
| 05/08/2002 | EP1203015A2 Human chaperone proteins |
| 05/08/2002 | EP1203010A1 Antisense modulation of fadd expression |
| 05/08/2002 | EP1203005A2 25 human secreted proteins |
| 05/08/2002 | EP1203004A1 HIGH AFFINITY TGF$g(g) NUCLEIC ACID LIGANDS AND INHIBITORS |
| 05/08/2002 | EP1202994A1 New compounds |
| 05/08/2002 | EP1202991A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 05/08/2002 | EP1202990A2 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 05/08/2002 | EP1202986A1 Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 05/08/2002 | EP1202980A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 05/08/2002 | EP1202976A1 Pyrazinones, compositions containing such compounds |
| 05/08/2002 | EP1202974A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/08/2002 | EP1202970A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 05/08/2002 | EP1202967A2 Sulfuric acid mono-[3-((1-(2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl)-hydroxy-methyl)-2-methoxy-phenyl]ester |